A new Lancet study titled Burden of MASLD and liver fibrosis: evidence from the Phenome India cohort published in The Lancet Regional Health - South Asia found that nearly four in 10 Indian adults have fatty liver or what scientifically is known as the metabolic dysfunction-associated steatotic liver disease (MASLD), formerly non as NAFLD or non-alcoholic fatty liver disease. The study also highlights a more worrying condition that a sizeable proportion of the Indian population already show signs of liver fibrosis. This is an early scarring process that could lead to cirrhosis or liver cancer if left unchecked. Lancet Study: How Was It Conducted?The study analyzed data from more than 7,700 adults across 27 cities in India. The study found that 38.9 per cent of participants had MASLD. The authors also noted that this figure is similar to the global estimates, however, is deeply concerning for India's population and size of the country, including the ever-rising burden of diabetes and obesity. The study also found that 6.3 per cent of people who live with MASLD had significant liver fibrosis, as compared to 1.7 per cent of those without fatty liver.Read: Indians Are At Most Risk Of Having Fatty Liver Disease, According To Doctor The study also found that 2.4 per cent of the entire population analyzed showed evidence of significant fibrosis. Why is this concerning? Fibrosis is a strong predicator of future complications. With the advancement of scarring, liver failure, cirrhosis, and liver caser risk also rises. Lancet Study: Who Are At Risk?The study found that people with obesity, diabetes, and central or abdominal fat were more likely to have MASLD. Obesity also was seen as the strongest risk factor, with likelihood rising steeply from overweight to severe obesity. Another factor was also age. Liver fibrosis was seen in adults over the age of 60 years and in people with diabetes, among whom nearly one in ten showed fibrotic changes. The study also showed that there was a presence of "Lean MASLD", which means it could also happen in people who are not overweight and have a normal body mass index. This is often linked to insulin resistance and visceral fat, which is the fat around internal organs. This tend to accumulate abdominal fat even at lower body weights. Lancet Study: Can MASLD And Other Liver Diseases Be Prevented?As per the authors of the study, MASLD is highly modifiable, especially at early stages. There are evidence that show that weight loss reduces liver fat and inflammation. Regular physical activity also improves insulin sensitivity, along with balanced diet. The diet must be consumed without or with very low sugar and ultra-processed food, which helps in control of diabetes and cholesterol and slows down disease progression. Authors also noted that people should get their fatty liver disease scanned regularly. Especially because MASLD is common among people with obesity and diabetes. There are many non-aggressive tools that could also detect fibrosis early.